This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It

It's time to highlight 2025's biggest percentage gainers and laggards on the IBD 50 list of growth stocks. Hospital operator Nutex Health (NUTX) wins the honor of strongest performer, followed by gold stock Aris Mining (ARMN). The former shot up more than 400%, and the latter more than 350%, and both stocks may have room to run higher.


Although the elite list identifies superior growth names in the stock market, not all stocks on the list produce triple-digit annual gains. The two IBD 50 stocks that rose the least in 2025 were Keros Therapeutics (KROS) and FTAI Aviation (FTAI).

Nutex Health stock gained an astounding 419% in 2025. It is just above a recent-high buy point of 158 in a long base that began in May.

On Nov. 18, Nutex restated 2024 financial results and first-quarter 2025 results that reflected higher revenue than previously stated.

Shares of the health care facilities operator plunged following a short-seller report in late November. Nutex addressed the report, saying the accusing company is an "entity that seems not to exist" based on publicly available information, and the "attack" was intended to generate profit from the declining share price.
Nutex stock is not for the faint of heart as it holds a 21-day average true range of nearly 9%, whereas The IBD Methodology seeks names with an ATR of 5% or less.

Nutex returned to profitability in 2024, and analysts forecast 45% earnings growth in 2025 followed by a 49% increase in 2026. The company owns and operates 26 specialty hospitals and outpatient facilities in 12 states and manages physician networks.

The second-highest IBD 50 performer last year was copper and gold stock Aris Mining, as it soared roughly 364%. The stock is currently far extended from its cup-with-handle base breakout in March after its meteoric climb.

The miner's profit growth ranged from 238% to 350% over the last three quarters. In addition, its third-quarter revenue growth accelerated to 88% from 7% five quarters prior.

Both Nutex and Aris Mining hold IBD Timeliness Ratings of A, indicating potential positive relative price performance over the next 12 months.
Impressive Names, But Lagging

Keros Therapeutics (KROS) ended the year around 29% higher, the smallest annual gain in the IBD 50. Keros stock has recovered only a portion of its 73% drop on Dec. 12, 2024, after its experimental lung hypertension drug caused a side effect of excess fluid buildup around patients' hearts.

The biopharmaceutical company develops treatments for hematological, pulmonary and cardiovascular disorders. It does not have any products approved by the U.S. Food and Drug Administration.

Lastly, FTAI Aviation ended 2025 nearly 37% higher, then reached a record high on Friday, topping the 200 price level.

The aerospace stock soared more than 14% on Dec. 29 in heavy volume and broke out of a first-stage cup-with-handle base with a 184.12 buy point. Shares topped the buy zone reaching to 193.33, according to MarketSurge pattern recognition. The stock bounced off its 10-week moving average after testing it for two straight weeks.

FTAI owns, leases and maintains commercial jet engines and aircraft. But on Dec. 29 it said it's launching a platform to convert its unused jet engines into turbines to meet artificial intelligence power demand. Production is expected to start in 2026.

https://www.investors.com/stock-lists/ibd-50/gold-stock-nutex-health-nutx-aris-mining-armn-biotech-ftai-kros/